USFDA2 Jun 2025, 10:24 am
Piramal Pharma's Aurora Facility Passes US FDA Inspection with Zero Form-483 Observations
AI Summary
Piramal Pharma Limited's Aurora, Canada facility underwent a US FDA GMP (Good Manufacturing Practices) Inspection from May 26, 2025, to May 30, 2025. The inspection concluded successfully with zero Form-483 observations and a No Action Indicated (NAI) designation. The company remains dedicated to upholding the highest standards of compliance.
Key Highlights
- US FDA conducted a GMP inspection at Piramal Pharma's Aurora facility in Canada
- Inspection completed with zero Form-483 observations
- Awarded No Action Indicated (NAI) designation
- Piramal Pharma remains committed to maintaining high compliance standards
- This information is for records and further reference